Pre-clinical studies in AML demonstrated that LSD1 contributes to the differentiation block that is the cardinal feature of the disease: LSD1 knockdown (KD) or LSD1 pharmacologic inhibition promotes differentiation of, in particular, AML cells with chromosomal translocations targeting MLL [4, 5]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.